1 month ago
15
Soumya Eswaran
Wed, July 15, 2026 astatine 8:11 AM CDT 3 min read
Laughing Water Capital, an concern absorption company, released its second-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. The 2nd 4th was exceptionally bully for the portfolio, with Class A concern successful Laughing Water Capital returning astir 39.8% nett of each fees and expenses, bringing the YTD instrumentality to astir 33.6% net. The SP500TR and R2000 returned astir 15.0% and 21.5%, respectively, successful the 2nd quarter. The awesome show was driven by 3 of the apical 5 positions being acquired, with its largest presumption astir doubling during the quarter. The missive emphasizes that patience tin often pb to profits successful an inefficient marketplace characterized by fluctuations, suggesting that investing successful undervalued stocks tin output bully semipermanent returns. In addition, delight cheque the portfolio's apical 5 holdings to cognize its champion picks successful 2026.
In its Q2 2026 capitalist letter, Laughing Water Capital highlighted Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated declaration improvement and manufacturing enactment that engages successful the aseptic capable and decorativeness of formulations and highly viscous sterile injectable pharmaceutical cause and aesculapian instrumentality products. On July 14, 2026, Lifecore Biomedical, Inc. (NASDAQ:LFCR) closed astatine $4.61 per share, reflecting a marketplace capitalization of $172.92 million. Lifecore Biomedical, Inc. (NASDAQ:LFCR) posted a one-month instrumentality of -16.49%, portion its shares mislaid 39.97% implicit the past 52 weeks.
Laughing Water Capital stated the pursuing regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) successful its Q2 2026 capitalist update:
"Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Lifecore, our under-utilized fill-finish Contract Drug Manufacturing Organization, continues to triumph caller concern astatine an awesome rate, and the marketplace continues to not care. I proceed to judge that erstwhile the caller concern wins construe into gross the operating leverage volition beryllium massive, and Lifecore volition make important cash. Of note, pursuing the extremity of the 4th the institution issued an 8K noting that holders of Series A Preferred Stock were redeeming their shares, and besides that the institution is evaluating strategical alternatives. I deliberation that a merchantability of the institution is apt successful the not-too-distant future."
Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 17 hedge money portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) astatine the extremity of the archetypal quarter, compared to 19 successful the erstwhile quarter. While we admit the imaginable of Lifecore Biomedical, Inc. (NASDAQ:LFCR) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·